schliessen

Filtern

 

Bibliotheken

Cover Image

Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure – A pooled analysis of clinical trials

The efficacy of quantified Crataegus extract in chronic heart failure (CHF) has been assessed in numerous clinical studies. The present pooled analysis evaluates the impact of baseline severity and gender on objective and patient-reported endpoints and associations between both types of outcomes in... Full description

Journal Title: Phytomedicine (Stuttgart) 2011, Vol.18 (14), p.1214-1219
Main Author: Eggeling, Thomas
Other Authors: Regitz-Zagrosek, Vera , Zimmermann, Andrea , Burkart, Martin
Format: Electronic Article Electronic Article
Language: English
Subjects:
Aged
Cardiac patients
Chemical properties
Clinical profile
Clinical Trials as Topic
Cohort Studies
Crataegus
Crataegus extract
Dyspnea - drug therapy
Dyspnea - physiopathology
Exercise Test
Exercise Tolerance
Fatigue - drug therapy
Fatigue - physiopathology
Female
Flavonoids - therapeutic use
Hawthorn extract
Hawthorns
Health aspects
Heart failure
Heart Failure - drug therapy
Heart Failure - physiopathology
Heart Function Tests
Humans
Long term
Male
Medicinal plants
Middle Aged
Patient outcomes
Physiological aspects
Plant Extracts - therapeutic use
Prognosis
Quality of Life
Severity of Illness Index
Sex Factors
Sex factors in disease
Subgroup analysis
Treatment Outcome
Usage
WS ® 1442
Quelle: Alma/SFX Local Collection
Publisher: Germany: Elsevier GmbH
ID: ISSN: 0944-7113
Link: https://www.ncbi.nlm.nih.gov/pubmed/21784624
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_902086620
title: Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure – A pooled analysis of clinical trials
format: Article
creator:
  • Eggeling, Thomas
  • Regitz-Zagrosek, Vera
  • Zimmermann, Andrea
  • Burkart, Martin
subjects:
  • Aged
  • Cardiac patients
  • Chemical properties
  • Clinical profile
  • Clinical Trials as Topic
  • Cohort Studies
  • Crataegus
  • Crataegus extract
  • Dyspnea - drug therapy
  • Dyspnea - physiopathology
  • Exercise Test
  • Exercise Tolerance
  • Fatigue - drug therapy
  • Fatigue - physiopathology
  • Female
  • Flavonoids - therapeutic use
  • Hawthorn extract
  • Hawthorns
  • Health aspects
  • Heart failure
  • Heart Failure - drug therapy
  • Heart Failure - physiopathology
  • Heart Function Tests
  • Humans
  • Long term
  • Male
  • Medicinal plants
  • Middle Aged
  • Patient outcomes
  • Physiological aspects
  • Plant Extracts - therapeutic use
  • Prognosis
  • Quality of Life
  • Severity of Illness Index
  • Sex Factors
  • Sex factors in disease
  • Subgroup analysis
  • Treatment Outcome
  • Usage
  • WS ® 1442
ispartof: Phytomedicine (Stuttgart), 2011, Vol.18 (14), p.1214-1219
description: The efficacy of quantified Crataegus extract in chronic heart failure (CHF) has been assessed in numerous clinical studies. The present pooled analysis evaluates the impact of baseline severity and gender on objective and patient-reported endpoints and associations between both types of outcomes in patients with early CHF. Available data from 687 individual patients treated with quantified Crataegus extract or placebo in ten studies were pooled. Treatment effects on physiologic outcome parameters and on symptoms were analysed for their association with baseline severity and gender. Changes in symptom scores were investigated with respect to their relation to physiologic outcome parameters. Results were compared with observations in a 3-year cohort study. Physiologic outcome parameters maximal workload (MWL), left ventricular ejection fraction (LVEF) and pressure-heart rate product increase (PHRPI) at 50 W ergometric exercise improved more in active treatment than in placebo patients. Magnitude of improvement was independent from baseline for LVEF but increased for MWL and PHRPI with baseline severity. Improvement of typical symptoms like reduced exercise tolerance, exertional dyspnea, weakness, fatigue, and palpitations improved more with active treatment and in patients with more severe symptoms. A weak association between improvements in MWL, PRHP, and symptoms could be demonstrated. Gender differences in treatment effects could be explained by baseline differences. Results of the pooled analysis are in agreement with observations in the cohort study. Crataegus extract treatment effects on physiologic outcomes and typical symptoms were modulated by baseline severity. Taking baseline differences into account, benefits were comparable in male and female patients with impaired exercise-tolerance in early chronic heart-failure.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0944-7113
fulltext: fulltext
issn:
  • 0944-7113
  • 1618-095X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.2889209
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_902086620
sourceformatXML
sourcesystemPC
galeidA276357786
sourcerecordidA276357786
originalsourceidFETCH-LOGICAL-c452t-562af90473f0c7949cd6f4a6937d66302f17e64fb2cc59f8ee70fd8828a2c4d13
addsrcrecordideNqFks2KFDEUhQtRnJ7RNxAJuJBZdJmk0kmVC6Ft_BkYEPwBdyGd3PSkSVd6ktRg73wDF76hT2KKmlm0iJLFheQ7J7m5p6qeEFwTTPiLbb2_OuzA1BQTUmNeY0rvVTPCSTvH3eLr_WqGO8bmgpDmpDpNaYsxYZ3AD6sTSkTLOGWz6sdrlcC7HlCCG4guH9B6yKgPGW2gNxDRLpjBqwwJXQ-qz846MGgVVVawGRKCbzkqnRFYCzon5HoEKvoDuiolI6ucHyKgX99_oiXah-CLWvXKH5JLKFiky-VOK49ydMqnR9UDWwo8vq1n1Ze3bz6v3s8vP7y7WC0v55otaJ4vOFW2w0w0FmvRsU4bbpniXSMM5w2mlgjgzK6p1ovOtgACW9O2tFVUM0Oas-r55LuP4XqAlOXOJQ3eqx7CkGSHKW45p7iQzyZyozxI19swNjzSckkFbxZCtLxQ9V-osgzsnA49WFf2jwTnR4LC5PKXGzWkJC8-fTxm2cTqGFKKYOU-up2KB0mwHMMgt3IKgxzDIDGXJQxF9vS2x2E9nt2J7qZfgJd_-GqXVXblKbHM7X_uryYxlDHdOIgyaQe9BuNiSYI0wf3b4DeKtdx-
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid902086620
display
typearticle
titleBaseline severity but not gender modulates quantified Crataegus extract effects in early heart failure – A pooled analysis of clinical trials
sourceAlma/SFX Local Collection
creatorEggeling, Thomas ; Regitz-Zagrosek, Vera ; Zimmermann, Andrea ; Burkart, Martin
creatorcontribEggeling, Thomas ; Regitz-Zagrosek, Vera ; Zimmermann, Andrea ; Burkart, Martin
descriptionThe efficacy of quantified Crataegus extract in chronic heart failure (CHF) has been assessed in numerous clinical studies. The present pooled analysis evaluates the impact of baseline severity and gender on objective and patient-reported endpoints and associations between both types of outcomes in patients with early CHF. Available data from 687 individual patients treated with quantified Crataegus extract or placebo in ten studies were pooled. Treatment effects on physiologic outcome parameters and on symptoms were analysed for their association with baseline severity and gender. Changes in symptom scores were investigated with respect to their relation to physiologic outcome parameters. Results were compared with observations in a 3-year cohort study. Physiologic outcome parameters maximal workload (MWL), left ventricular ejection fraction (LVEF) and pressure-heart rate product increase (PHRPI) at 50 W ergometric exercise improved more in active treatment than in placebo patients. Magnitude of improvement was independent from baseline for LVEF but increased for MWL and PHRPI with baseline severity. Improvement of typical symptoms like reduced exercise tolerance, exertional dyspnea, weakness, fatigue, and palpitations improved more with active treatment and in patients with more severe symptoms. A weak association between improvements in MWL, PRHP, and symptoms could be demonstrated. Gender differences in treatment effects could be explained by baseline differences. Results of the pooled analysis are in agreement with observations in the cohort study. Crataegus extract treatment effects on physiologic outcomes and typical symptoms were modulated by baseline severity. Taking baseline differences into account, benefits were comparable in male and female patients with impaired exercise-tolerance in early chronic heart-failure.
identifier
0ISSN: 0944-7113
1EISSN: 1618-095X
2DOI: 10.1016/j.phymed.2011.06.022
3PMID: 21784624
languageeng
publisherGermany: Elsevier GmbH
subjectAged ; Cardiac patients ; Chemical properties ; Clinical profile ; Clinical Trials as Topic ; Cohort Studies ; Crataegus ; Crataegus extract ; Dyspnea - drug therapy ; Dyspnea - physiopathology ; Exercise Test ; Exercise Tolerance ; Fatigue - drug therapy ; Fatigue - physiopathology ; Female ; Flavonoids - therapeutic use ; Hawthorn extract ; Hawthorns ; Health aspects ; Heart failure ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Heart Function Tests ; Humans ; Long term ; Male ; Medicinal plants ; Middle Aged ; Patient outcomes ; Physiological aspects ; Plant Extracts - therapeutic use ; Prognosis ; Quality of Life ; Severity of Illness Index ; Sex Factors ; Sex factors in disease ; Subgroup analysis ; Treatment Outcome ; Usage ; WS ® 1442
ispartofPhytomedicine (Stuttgart), 2011, Vol.18 (14), p.1214-1219
rights
02011 Elsevier GmbH
1Copyright © 2011 Elsevier GmbH. All rights reserved.
2COPYRIGHT 2011 Urban & Fischer Verlag
lds50peer_reviewed
citedbyFETCH-LOGICAL-c452t-562af90473f0c7949cd6f4a6937d66302f17e64fb2cc59f8ee70fd8828a2c4d13
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21784624$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Eggeling, Thomas
1Regitz-Zagrosek, Vera
2Zimmermann, Andrea
3Burkart, Martin
title
0Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure – A pooled analysis of clinical trials
1Phytomedicine (Stuttgart)
addtitlePhytomedicine
descriptionThe efficacy of quantified Crataegus extract in chronic heart failure (CHF) has been assessed in numerous clinical studies. The present pooled analysis evaluates the impact of baseline severity and gender on objective and patient-reported endpoints and associations between both types of outcomes in patients with early CHF. Available data from 687 individual patients treated with quantified Crataegus extract or placebo in ten studies were pooled. Treatment effects on physiologic outcome parameters and on symptoms were analysed for their association with baseline severity and gender. Changes in symptom scores were investigated with respect to their relation to physiologic outcome parameters. Results were compared with observations in a 3-year cohort study. Physiologic outcome parameters maximal workload (MWL), left ventricular ejection fraction (LVEF) and pressure-heart rate product increase (PHRPI) at 50 W ergometric exercise improved more in active treatment than in placebo patients. Magnitude of improvement was independent from baseline for LVEF but increased for MWL and PHRPI with baseline severity. Improvement of typical symptoms like reduced exercise tolerance, exertional dyspnea, weakness, fatigue, and palpitations improved more with active treatment and in patients with more severe symptoms. A weak association between improvements in MWL, PRHP, and symptoms could be demonstrated. Gender differences in treatment effects could be explained by baseline differences. Results of the pooled analysis are in agreement with observations in the cohort study. Crataegus extract treatment effects on physiologic outcomes and typical symptoms were modulated by baseline severity. Taking baseline differences into account, benefits were comparable in male and female patients with impaired exercise-tolerance in early chronic heart-failure.
subject
0Aged
1Cardiac patients
2Chemical properties
3Clinical profile
4Clinical Trials as Topic
5Cohort Studies
6Crataegus
7Crataegus extract
8Dyspnea - drug therapy
9Dyspnea - physiopathology
10Exercise Test
11Exercise Tolerance
12Fatigue - drug therapy
13Fatigue - physiopathology
14Female
15Flavonoids - therapeutic use
16Hawthorn extract
17Hawthorns
18Health aspects
19Heart failure
20Heart Failure - drug therapy
21Heart Failure - physiopathology
22Heart Function Tests
23Humans
24Long term
25Male
26Medicinal plants
27Middle Aged
28Patient outcomes
29Physiological aspects
30Plant Extracts - therapeutic use
31Prognosis
32Quality of Life
33Severity of Illness Index
34Sex Factors
35Sex factors in disease
36Subgroup analysis
37Treatment Outcome
38Usage
39WS ® 1442
issn
00944-7113
11618-095X
fulltexttrue
rsrctypearticle
creationdate2011
recordtypearticle
recordideNqFks2KFDEUhQtRnJ7RNxAJuJBZdJmk0kmVC6Ft_BkYEPwBdyGd3PSkSVd6ktRg73wDF76hT2KKmlm0iJLFheQ7J7m5p6qeEFwTTPiLbb2_OuzA1BQTUmNeY0rvVTPCSTvH3eLr_WqGO8bmgpDmpDpNaYsxYZ3AD6sTSkTLOGWz6sdrlcC7HlCCG4guH9B6yKgPGW2gNxDRLpjBqwwJXQ-qz846MGgVVVawGRKCbzkqnRFYCzon5HoEKvoDuiolI6ucHyKgX99_oiXah-CLWvXKH5JLKFiky-VOK49ydMqnR9UDWwo8vq1n1Ze3bz6v3s8vP7y7WC0v55otaJ4vOFW2w0w0FmvRsU4bbpniXSMM5w2mlgjgzK6p1ovOtgACW9O2tFVUM0Oas-r55LuP4XqAlOXOJQ3eqx7CkGSHKW45p7iQzyZyozxI19swNjzSckkFbxZCtLxQ9V-osgzsnA49WFf2jwTnR4LC5PKXGzWkJC8-fTxm2cTqGFKKYOU-up2KB0mwHMMgt3IKgxzDIDGXJQxF9vS2x2E9nt2J7qZfgJd_-GqXVXblKbHM7X_uryYxlDHdOIgyaQe9BuNiSYI0wf3b4DeKtdx-
startdate2011
enddate2011
creator
0Eggeling, Thomas
1Regitz-Zagrosek, Vera
2Zimmermann, Andrea
3Burkart, Martin
general
0Elsevier GmbH
1Urban & Fischer Verlag
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
87X8
sort
creationdate2011
titleBaseline severity but not gender modulates quantified Crataegus extract effects in early heart failure – A pooled analysis of clinical trials
authorEggeling, Thomas ; Regitz-Zagrosek, Vera ; Zimmermann, Andrea ; Burkart, Martin
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c452t-562af90473f0c7949cd6f4a6937d66302f17e64fb2cc59f8ee70fd8828a2c4d13
rsrctypearticles
prefilterarticles
languageeng
creationdate2011
topic
0Aged
1Cardiac patients
2Chemical properties
3Clinical profile
4Clinical Trials as Topic
5Cohort Studies
6Crataegus
7Crataegus extract
8Dyspnea - drug therapy
9Dyspnea - physiopathology
10Exercise Test
11Exercise Tolerance
12Fatigue - drug therapy
13Fatigue - physiopathology
14Female
15Flavonoids - therapeutic use
16Hawthorn extract
17Hawthorns
18Health aspects
19Heart failure
20Heart Failure - drug therapy
21Heart Failure - physiopathology
22Heart Function Tests
23Humans
24Long term
25Male
26Medicinal plants
27Middle Aged
28Patient outcomes
29Physiological aspects
30Plant Extracts - therapeutic use
31Prognosis
32Quality of Life
33Severity of Illness Index
34Sex Factors
35Sex factors in disease
36Subgroup analysis
37Treatment Outcome
38Usage
39WS ® 1442
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Eggeling, Thomas
1Regitz-Zagrosek, Vera
2Zimmermann, Andrea
3Burkart, Martin
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7MEDLINE - Academic
jtitlePhytomedicine (Stuttgart)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Eggeling, Thomas
1Regitz-Zagrosek, Vera
2Zimmermann, Andrea
3Burkart, Martin
formatjournal
genrearticle
ristypeJOUR
atitleBaseline severity but not gender modulates quantified Crataegus extract effects in early heart failure – A pooled analysis of clinical trials
jtitlePhytomedicine (Stuttgart)
addtitlePhytomedicine
date2011
risdate2011
volume18
issue14
spage1214
epage1219
pages1214-1219
issn0944-7113
eissn1618-095X
abstractThe efficacy of quantified Crataegus extract in chronic heart failure (CHF) has been assessed in numerous clinical studies. The present pooled analysis evaluates the impact of baseline severity and gender on objective and patient-reported endpoints and associations between both types of outcomes in patients with early CHF. Available data from 687 individual patients treated with quantified Crataegus extract or placebo in ten studies were pooled. Treatment effects on physiologic outcome parameters and on symptoms were analysed for their association with baseline severity and gender. Changes in symptom scores were investigated with respect to their relation to physiologic outcome parameters. Results were compared with observations in a 3-year cohort study. Physiologic outcome parameters maximal workload (MWL), left ventricular ejection fraction (LVEF) and pressure-heart rate product increase (PHRPI) at 50 W ergometric exercise improved more in active treatment than in placebo patients. Magnitude of improvement was independent from baseline for LVEF but increased for MWL and PHRPI with baseline severity. Improvement of typical symptoms like reduced exercise tolerance, exertional dyspnea, weakness, fatigue, and palpitations improved more with active treatment and in patients with more severe symptoms. A weak association between improvements in MWL, PRHP, and symptoms could be demonstrated. Gender differences in treatment effects could be explained by baseline differences. Results of the pooled analysis are in agreement with observations in the cohort study. Crataegus extract treatment effects on physiologic outcomes and typical symptoms were modulated by baseline severity. Taking baseline differences into account, benefits were comparable in male and female patients with impaired exercise-tolerance in early chronic heart-failure.
copGermany
pubElsevier GmbH
pmid21784624
doi10.1016/j.phymed.2011.06.022
tpages6